Cocrystal Pharma (NASDAQ:COCP – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.23, Zacks reports.
Cocrystal Pharma Trading Down 1.1 %
NASDAQ COCP opened at $1.46 on Monday. The stock has a market cap of $14.89 million, a price-to-earnings ratio of -0.79 and a beta of 2.35. The company has a 50-day moving average price of $1.81 and a two-hundred day moving average price of $1.93. Cocrystal Pharma has a 52 week low of $1.35 and a 52 week high of $3.26.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Cocrystal Pharma in a report on Wednesday, January 22nd.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Featured Articles
- Five stocks we like better than Cocrystal Pharma
- Utilities Stocks Explained – How and Why to Invest in Utilities
- AT&T and Verizon: 2 Telecom Titans for a Tariff-Proof Play
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 High-Performing Tech ETFs to Diversify Your Portfolio
- How to Find Undervalued Stocks
- Netflix Poised for Significant Rally as a Safe Haven Stock
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
